Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Novel therapeutic strategies for AML in 2012
Martin S. Tallman
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel therapeutic strategies for AML in 2012'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Novel Therapeutics
100%
Young Patients
100%
Cytarabine
100%
First Complete Remission
100%
Molecular Targets
50%
Effective Treatment
50%
Improved Outcomes
50%
Molecular Pathogenesis
50%
Acute Myeloid Leukemia
50%
Effective Strategies
50%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
50%
Standard of Care
50%
Anthracyclines
50%
Prognostic Factors
50%
Cure Rate
50%
Disease Biology
50%
Novel Mechanism of Action
50%
Daunorubicin
50%
Initial Description
50%
Dose Intensification
50%
Post-remission
50%
Medicine and Dentistry
Cytarabine
100%
Acute Myelogenous Leukemia
100%
Acute Myeloid Leukemia
50%
Anthracycline
50%
Hematopoietic Cell
50%
Molecular Pathology
50%
Prognostic Factor
50%
Cell Transplantation
50%
Liposomal Daunorubicin
50%
Drug Dose Intensification
50%
Diseases
50%
Immunology and Microbiology
Myeloid
100%
Cell Transplantation
100%
Drug Dose Intensification
100%
Hematopoietic Cell
100%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Cytarabine
66%
Daunorubicin
33%
Molecular Target
33%
Molecular Pathology
33%
Acute Myeloid Leukemia
33%
Anthracycline
33%
Diseases
33%